Literature DB >> 18420501

Clinical practice. Irritable bowel syndrome.

Emeran A Mayer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18420501      PMCID： PMC3816529          DOI： 10.1056/NEJMcp0801447

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  36 in total

1.  Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study.

Authors:  Smita L S Halder; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; L Joseph Melton; Nicholas J Talley
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

2.  Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.

Authors:  Pankaj Jay Pasricha
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

3.  The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.

Authors:  Mark Pimentel; Sandy Park; James Mirocha; Sunanda V Kane; Yuthana Kong
Journal:  Ann Intern Med       Date:  2006-10-17       Impact factor: 25.391

Review 4.  The serotonin signaling system: from basic understanding to drug development for functional GI disorders.

Authors:  Michael D Gershon; Jan Tack
Journal:  Gastroenterology       Date:  2007-01       Impact factor: 22.682

Review 5.  Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

Authors:  Lin Chang; William D Chey; Lucinda Harris; Kevin Olden; Christina Surawicz; Philip Schoenfeld
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

Review 6.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

Authors:  E M M Quigley; B Flourie
Journal:  Neurogastroenterol Motil       Date:  2007-03       Impact factor: 3.598

Review 7.  Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.

Authors:  J Tack; M Fried; L A Houghton; J Spicak; G Fisher
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

8.  Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Authors:  Viola Andresen; Michael Camilleri; Irene A Busciglio; April Grudell; Duane Burton; Sanna McKinzie; Amy Foxx-Orenstein; Caroline B Kurtz; Vineeta Sharma; Jeffrey M Johnston; Mark G Currie; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2007-07-03       Impact factor: 22.682

9.  The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects.

Authors:  Anna Kassinen; Lotta Krogius-Kurikka; Harri Mäkivuokko; Teemu Rinttilä; Lars Paulin; Jukka Corander; Erja Malinen; Juha Apajalahti; Airi Palva
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

Review 10.  Guidelines on the irritable bowel syndrome: mechanisms and practical management.

Authors:  R Spiller; Q Aziz; F Creed; A Emmanuel; L Houghton; P Hungin; R Jones; D Kumar; G Rubin; N Trudgill; P Whorwell
Journal:  Gut       Date:  2007-05-08       Impact factor: 23.059
View more
  84 in total

Review 1.  Gut feelings: the emerging biology of gut-brain communication.

Authors:  Emeran A Mayer
Journal:  Nat Rev Neurosci       Date:  2011-07-13       Impact factor: 34.870

2.  Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.

Authors:  Jeffrey M Lackner; James Jaccard; Laurie Keefer; Darren M Brenner; Rebecca S Firth; Gregory D Gudleski; Frank A Hamilton; Leonard A Katz; Susan S Krasner; Chang-Xing Ma; Christopher D Radziwon; Michael D Sitrin
Journal:  Gastroenterology       Date:  2018-04-25       Impact factor: 22.682

3.  MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.

Authors:  QiQi Zhou; Stefan Costinean; Carlo M Croce; Alan R Brasier; Shehzad Merwat; Scott A Larson; Sarpreet Basra; G Nicholas Verne
Journal:  Gastroenterology       Date:  2014-09-30       Impact factor: 22.682

4.  A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders.

Authors:  Edith Lahner; Stefano Bellentani; Rudy De Bastiani; Cesare Tosetti; Michele Cicala; Gianluca Esposito; Paolo Arullani; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

5.  Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.

Authors:  Amanda M Pattison; Erik S Blomain; Dante J Merlino; Fang Wang; Mary Ann S Crissey; Crystal L Kraft; Jeff A Rappaport; Adam E Snook; John P Lynch; Scott A Waldman
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

6.  Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.

Authors:  Hilary Schenck Eidam; John Russell; Kaushik Raha; Michael DeMartino; Donghui Qin; Huiping Amy Guan; Zhiliu Zhang; Gong Zhen; Haiyu Yu; Chengde Wu; Yan Pan; Gerard Joberty; Nico Zinn; Sylvie Laquerre; Sharon Robinson; Angela White; Amanda Giddings; Ehsan Mohammadi; Beverly Greenwood-Van Meerveld; Allen Oliff; Sanjay Kumar; Mui Cheung
Journal:  ACS Med Chem Lett       Date:  2018-05-24       Impact factor: 4.345

Review 7.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

8.  The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Laurie Keefer; James Jaccard; Rebecca Firth; Darren Brenner; Jason Bratten; Laura J Dunlap; Changxing Ma; Mark Byroads
Journal:  Contemp Clin Trials       Date:  2012-07-28       Impact factor: 2.226

9.  Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Chang-Xing Ma; Laurie Keefer; Darren M Brenner; Gregory D Gudleski; Nikhil Satchidanand; Rebecca Firth; Michael D Sitrin; Leonard Katz; Susan S Krasner; Sarah K Ballou; Bruce D Naliboff; Emeran A Mayer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

10.  Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.

Authors:  Jeffrey M Lackner; James Jaccard; Charles Baum
Journal:  Value Health       Date:  2012-11-30       Impact factor: 5.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.